Microvascular Thrombosis and Cardiac Allograft Vasculopathy in Rat Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 25, Issue 10, 2006, Pages 1213-1222

  Labarrere, Carlos A ^a   Ortiz, Miguel A ^a   Ruzmetov, Nargiz ^a   Sosa, Marcelo J ^a   Campana, Gonzalo ^a   Terry, Colin ^a   Baldridge, Lee Ann ^b   Antonopoulos, Roula ^a   DiCarlo, Hector L ^a  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; CYCLOSPORIN; FIBRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HYPERCOAGULABILITY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MALE; MICROANGIOPATHY; MICROSCOPY; MICROVASCULATURE; NONHUMAN; ORGAN DONOR; PATHOGENESIS; PRIORITY JOURNAL; RAT; THROMBOSIS;

ANIMALS; ANTITHROMBINS; CAPILLARIES; CORONARY DISEASE; CORONARY THROMBOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FIBRIN; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MYOCARDIUM; RATS; RATS, INBRED STRAINS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 33749515756     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.06.013     Document Type: Article

References (32)

1. Eisen H., Kobashigawa J., Starling R.C., Valantine H.A., and Mancini D.M. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 37 suppl (2005) 4S-17S
2. Taylor D.O., Edwards L.B., Boucek M.M., Trulock E.P., Keck B.M., and Hertz M.I. The registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23 (2004) 796-803
3. Labarrere C.A., Torry R.J., Nelson D.R., et al. Vascular antithrombin and clinical outcome in heart transplant patients. Am J Cardiol 87 (2001) 425-431
4. Labarrere C.A., Nelson D.R., Pitts D.E., Kirlin P.C., and Halbrook H. Immunohistochemical model to predict risk for coronary artery disease and failure in heart transplant patients. Am J Transplant 1 (2001) 251-259
5. Labarrere C.A., Nelson D.R., and Park J.W. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol 16 (2001) 110-117
6. Labarrere C.A., and Deng M.C. Microvascular prothrombogenicity and transplant coronary artery disease. Transplant Immunol 9 (2002) 243-249
7. Labarrere C.A., Nelson D.R., and Spear K.L. Non-immunologic vascular failure of the transplanted heart. J Heart Lung Transplant 22 (2003) 236-240
8. Holschermann H., Bohle R.M., Zeller H., et al. In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am J Pathol 154 (1999) 211-220
9. Holschermann H., Bohle R.M., Schmidt H., et al. Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 102 (2000) 357-363
10. Aramaki O., Takayama T., Yokoyama T., et al. Intravenous administration of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts. Transplant Proc 34 (2002) 1409-1410
11. Aramaki O., Takayama T., Yokoyama T., et al. High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells. Transplantation 75 (2003) 217-220
12. Ono K., and Lindsey E.S. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 57 (1969) 225-229
13. Poston Jr. R.S., Billingham M.E., Pollard J., Hoyt E.G., and Robbins R.C. Effects of increased ICAM-1 on reperfusion injury and chronic graft vascular disease. Ann Thorac Surg 64 (1997) 1004-1012
14. Labarrere C.A., Lee J.B., Nelson D.R., Al-Hassani M., Miller S.J., and Pitts D.E. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 360 (2002) 1462-1467
15. Balsam L.B., Mokhtari G.K., Jones S., et al. Early inhibition of caspase-3 activity lessens the development of graft coronary artery disease. J Heart Lung Transplant 24 (2005) 827-832
16. Labarrere C.A., Nelson D.R., and Faulk W.P. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 105 (1998) 207-213
17. Labarrere C.A., Nelson D.R., Cox C.J., Pitts D., Kirlin P., and Halbrook H. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 284 (2000) 457-464
18. Yen M.H., Pilkington G., Starling R.C., et al. Increased tissue factor expression predicts development of cardiac allograft vasculopathy. Circulation 106 (2002) 1379-1383
19. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
20. Pages G., and Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 65 (2005) 564-573
21. Hashimoto E., Ogita T., Nakaoka T., Matsuoka R., Takao A., and Kira Y. Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. Am J Physiol 267 (1994) H1948-H1954
22. Li J., Brown L.F., Hibberd M.G., Grossman J.D., Morgan J.P., and Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 270 (1996) H1803-H1811
23. Shinohara K., Shinohara T., Mochizuki N., et al. Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels 11 (1996) 113-122
24. Torry R.J., Bai L., Miller S.J., Labarrere C.A., Nelson D., and Torry D.S. Increased vascular endothelial growth factor expression in human hearts with microvascular fibrin. J Mol Cell Cardiol 33 (2001) 175-184
25. Salom R.N., Maguire J.A., and Hancock W.W. Endothelial activation and cytokine expression in human acute cardiac allograft rejection. Pathology 30 (1998) 24-29
26. Hackert T., Werner J., Uhl W., Gebhard M.M., Buchler M.W., and Schmidt J. Reduction of ischemia/reperfusion injury by antithrombin III after experimental pancreas transplantation. Am J Surg 189 (2005) 92-97
27. Zuo X.J., Okada Y., Nicolaidou E., et al. Antithrombin III inhibits T- and B-lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Transplant Proc 31 (1999) 816-817
28. Okada Y., Zuo X.J., Marchevsky A.M., et al. Antithrombin III treatment improves parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection. Transplantation 67 (1999) 526-528
29. Oelschlager C., Romisch J., Staubitz A., et al. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 99 (2002) 4015-4020
30. Holschermann H., Hilgendorff A., Kemkes-Matthes B., et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 69 (2000) 1830-1836
31. Elenius K., Vainio S., Laato M., Salmivirta M., Thesleff I., and Jalkanen M. Induced expression of syndecan in healing wounds. J Cell Biol 114 (1991) 585-595
32. Kojima T., Takagi A., Maeda M., et al. Plasma levels of syndecan-4 (ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost 85 (2001) 793-799